Tenax Therapeutics, Inc. (TENX)
| Market Cap | 29.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.81M |
| Shares Out | 12.43M |
| EPS (ttm) | -1.11 |
| PE Ratio | n/a |
| Forward PE | 17.79 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $2.31 |
| Previous Close | $2.49 |
| Change ($) | -0.18 |
| Change (%) | -7.23% |
| Day's Open | 2.44 |
| Day's Range | 2.21 - 2.49 |
| Day's Volume | 1,115,695 |
| 52-Week Range | 0.45 - 2.58 |
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) to host conf. call & live audio webcast on Jan 21, 2021, at 4:30 pm to discuss acquisition of PH Precision Med
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-base...
Tenax Therapeutics (TENX) stock is flying high on Tuesday after announcing it has acquired biotech company PH Precision Med. The post TENX Stock: 8 Things to Know About Tenax Therapeutics and ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) acquires PH Precision Med (PHPM), adding imatinib to its pipeline. Stuart Rich, MD joins as CMO.
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) today reported financial results for the third quarter 2020 and provided a business update
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces HELP Study presented at American Heart Association (AHA) Scientific Sessions available Nov. 13th
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) will host a virtual R&D webinar for analysts and investors on Wednesday, November 18, 2020 at 4:30 p.m. EST
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces amendment to Orion License Agreement adding oral levosimendan.
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces presentation of Phase 2 HELP Study at virtual meeting of HFSA on Saturday, Oct 3, 2020 @ 4:30 pm EDT
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc.
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) Announces $8MM Registered Direct and PIPE Offering with single healthcare-focused institutional investor
Shares of nano-cap Tenax Therapeutics Inc (NASDAQ: TENX), are advancing strongly Tuesday in the wake of a positive clinical readout.
About TENX
Tenax Therapeutics, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical... [Read more...]
| Industry Biotechnology | Founded 1967 |
| CEO Anthony DiTonno | Employees 9 |
| Stock Exchange NASDAQ | Ticker Symbol TENX |
Analyst Forecasts
According to 2 analysts, the average rating for TENX stock is "Buy." The 12-month stock price forecast is 3.67, which is an increase of 58.87% from the latest price.